EPOCH 45: BIOTECH MARKET RESEARCH ($ICVX)

Icosavax

Mark your calendars for the anticipated interim results from Icosavax's Phase 2 clinical trial of IVX-A12, a dual RSV/hMPV vaccine.  This study holds promise in the red hot space of respiratory disease prevention, and the market is eagerly awaiting the data's release. Options pricing indicates a potential move of over 60% - investors are poised for a significant market impact.

Every Monday we are out with public biotech research, profiling biotech companies with near term catalysts. This will focus primarily on the major market moving biotech events such as data readouts from the major scientific conferences as well as potential regulatory approvals.

We will not offer specific trading advice (and we do not hold any publicly traded biotech equity), but rather flag emerging events that will likely materially drive stock prices (sometimes +/-100% in either direction).

Be sure to SUBSCRIBE to not miss.

HOW TO PLAY BIOTECH APPROVAL/DATA READOUTS ANNOUNCEMENTS

While biotech equities will move on news of announcement, often if there is high conviction in a positive read, a large run up ahead of the news will occur and the actual event turns into a sell the news event. Sometimes, investors wait for the actual event to make a long/short decision. And obviously if the news is disappointing (more often than not) the stock will tank.

This is not financial advice so you will have to make your own call on how to best play these events.

ALERT: Icosavax ($ICVX) Phase 2 interim readout from RSV/hMPV vaccine trial

DATE: Q4 2023

IMPLIED VOLATILITY: +/- 60%

BACKGROUND: